Gene Modulation in HBV-Gene Modulation in HBV

Video Transcription

Video Summary

The webinar on gene modulation in hepatitis B, led by Dr. Grace Wong and Dr. Louie Mak, addressed the substantial unmet needs in current HPV therapeutics, emphasizing the complex challenge of achieving a functional cure due to the persistent presence of CCC DNA and integrated DNA in hepatocytes. They discussed novel approaches using gene modulation and editing technologies, such as epigenetic modifiers and CRISPR-Cas9, aiming to clear these viral reservoirs. Such technologies targeting CCC DNA are advancing towards clinical trials with promising initial safety data. Challenges highlighted include the delivery of these therapies via lipid nanoparticles and potential side effects like chromosomal translocation or infusion reactions. The webinar stressed the need for standardized biomarkers and addressed cost and accessibility concerns in low-income regions, while noting that these advanced therapies are entering clinical trial stages, marking significant progress towards achieving functional cures for HPV.

Keywords

gene modulation

hepatitis B

CRISPR-Cas9

CCC DNA

clinical trials